Page:NIOSH Manual of Analytical Methods - Chapter K.pdf/4

 isocyanate-containing intermediates formed during polyurethane production. In addition, isocyanate-containing mixtures of vapors and aerosols can be generated during the thermal degradation of polyurethane coatings and plastics. The capability to measure all isocyanate-containing substances in air, whether they are in monomer, prepolymer, polyisocyanate, oligomer, and/or intermediate forms, is important when assessing a worker's total airborne isocyanate exposure. 3. ISOCYANATE EXPOSURE RELATED HEALTH EFFECTS Exposure to isocyanates is irritating to the skin, mucous membranes, eyes, and respiratory tract.6,7 The most common adverse health outcome associated with isocyanate exposure is asthma due to sensitization; less prevalent are contact dermatitis (both irritant and allergic forms) and hypersensitivity pneumonitis (HP).7,8,9 Contact dermatitis can result in symptoms such as rash, itching, hives, and swelling of the extremities.6,9 A worker suspected of having isocyanate-induced asthma/sensitization will exhibit the traditional symptoms of acute airway obstruction, e.g., coughing, wheezing, shortness of breath, tightness in the chest, and nocturnal awakening.6,8 An isocyanate-exposed worker may first develop an asthmatic condition (i.e., become sensitized) after a single (acute) exposure, but sensitization usually takes a few months to several years of exposure.6,8,10,11,12 The asthmatic reaction may occur minutes after exposure (immediate), several hours after exposure (late), or a combination of both immediate and late components after exposure (dual).8,11 The late asthmatic reaction is the most common, occurring in approximately 40% of isocyanate sensitized workers.13 After sensitization, any exposure, even to levels below an occupational exposure limit or standard, can produce an asthmatic response which may be life threatening. Experience with isocyanates has shown that monomeric, prepolymeric and polyisocyanate species are capable of producing respiratory sensitization in exposed workers.14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30 Since the intermediates may be chemically similar to these compounds, it is reasonable to assume that they may also produce this condition. Prevalence estimates for isocyanate-induced asthma in exposed worker populations vary considerably: from 5% to 10% in diisocyanate production facilities10,31 to 25% in polyurethane production plants31,32 and 30% in polyurethane seatcover operations.33 The scientific literature contains a limited amount of animal data suggesting that dermal exposure to diisocyanates may produce respiratory sensitization.34,35,36,37 This finding has not been tested in dermally exposed workers. Hypersensitivity pneumonitis (HP) also has been described in workers exposed to isocyanates.38,39,40,41 Currently, the prevalence of isocyanate-induced HP in the worker population is unknown, and is considered to be rare when compared to the prevalence rates for isocyanate-induced asthma.9 Whereas asthma is an obstructive respiratory disease usually affecting the bronchi, HP is a restrictive respiratory disease affecting the lung parenchyma (bronchioles and alveoli). The initial symptoms associated with isocyanate-induced HP are flu-like, including shortness of breath, non-productive cough, fever, chills, sweats, malaise, and nausea.8,9 After the onset of HP, prolonged and/or repeated exposures may lead to an irreversible decline in pulmonary function and lung compliance, and to the development of diffuse interstitial fibrosis.8,9 Early diagnosis is difficult since many aspects of HP, i.e., the flu-like symptoms and the changes in pulmonary function, are manifestations common to many other respiratory diseases and conditions. The only effective intervention for workers with isocyanate-induced sensitization (asthma) or HP is cessation of all isocyanate exposure. This can be accomplished by removing the worker from the work environment where isocyanate exposure occurs, or by providing the worker with supplied-air respiratory protection and preventing any dermal exposures. 4. EXPOSURE CRITERIA FOR DIISOCYANATES 1/15/98

118

NIOSH Manual of Analytical Methods